A new day for precision oncology

A new world of NGS

Brought to you by ThermoFisher Scientific


Next-Generation Solution for Genomic Profiling

Oncomine Precision Assay on the Ion Torrent Genexus System provides a complete NGS testing workflow that lets every lab go from specimen to report in a single day*. Now your laboratory can produce NGS results in the same time as testing for single-gene biomarkers like PD-L1.

Solution Features

Get Results in a Day

Get a profile for 50 key genes in one day. See the complete picture by combining results for single-gene biomarkers like PD-L1 with other important biomarkers like BRAF, KRAS, ALK, NTRK, ROS1, and RET among others.

Get Results for More of Your Samples

Oncomine Solutions offers the lowest sample input requirement of any NGS platform. Now you can submit more of your samples for testing and no longer need to deal with high test failure rates, even when tissue is very limited.

Enjoy the Simplicity

Get a clear and concise report that presents all relevant variants with annotated information about targeted therapies, medical guidelines, and enrollment in ongoing clinical trials.



Don't let precious samples go untested 

Did you know that some NGS send-out labs have test failure rates of 20% due to high input requirements?

At that rate, 1 out of 5 samples do not receive a result, and many more are not tested at all due to lack of tissue availability.

Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10ng of nucleic acid input. That means you can get an NGS result for more of the precious samples you have.



Learn more about Oncomine Solutions

Contact a Representative

References:

1.  Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2.  J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3.  Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4.  Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.

 

For Research Use Only.  Not for use in diagnostic procedures.  *Specimen-to-report workflow will be available after the Ion Torrent Genexus System and integrated reporting capabilities are added in 2020.